Insider Trading disclosures for Regeneron Pharmaceuticals, Inc.

The latest disclosure was made by Arthur Frederick Ryan in Regeneron Pharmaceuticals, Inc. where a trade of 1,958 Non-Qualified Stock Option (right to buy) done was reported to US exchanges on Jan. 2, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Arthur Frederick Ryan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
Arthur Frederick Ryan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	17,748 (0%)	0%		0	Common Stock
Joseph L. Goldstein	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
Joseph L. Goldstein	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	6,548 (0%)	0%		0	Common Stock
N. Anthony Coles	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
N. Anthony Coles	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	1,559 (0%)	0%		0	Common Stock
Michael S. Brown	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	1,548 (0%)	0%		0	Common Stock
Michael S. Brown	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
Craig B. Thompson	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	620 (0%)	0%		0	Common Stock
Craig B. Thompson	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
Christine A. Poon	Director		02 Jan 2025	14	2,186 (0%)	0%		0	Common Stock
Christine A. Poon	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	2,352 (0%)	0%		0	Common Stock
Christine A. Poon	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
David P. Schenkein	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
David P. Schenkein	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	448 (0%)	0%		0	Common Stock
Bonnie L. Bassler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
Bonnie L. Bassler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	1,548 (0%)	0%		0	Common Stock
Huda Y. Zoghbi	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	1,548 (0%)	0%		0	Common Stock
Huda Y. Zoghbi	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
Kathryn Guarini	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	166	448 (0%)	0%		0	Common Stock
Kathryn Guarini	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
George L. Sing	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share.	31 Dec 2024	3,338	29,610 (0%)	0%	413.3	1,379,696	Common Stock
George L. Sing	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Dec 2024	1,958	1,958	-		-	Non-Qualified Stock Option (right to buy)
George L. Sing	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Dec 2024	3,338	0	-		-	Non-Qualified Stock Option (right to buy)
George L. Sing	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Dec 2024	166	27,828 (0%)	0%		0	Common Stock
George L. Sing	Director	Payment of exercise price or tax liability using portion of securities received from the company at price $ 708.19 per share.	31 Dec 2024	1,948	27,662 (0%)	0%	708.2	1,379,554	Common Stock
Marion McCourt	EVP Commercial	Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share.	16 Dec 2024	759	14,230 (0%)	0%	730.8	554,685	Common Stock
J. Joseph Larosa	EVP General Counsel and Secret	Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share.	16 Dec 2024	702	30,075 (0%)	0%	730.8	513,029	Common Stock
P. Van Plew Daniel	EVP & General Mgr, Industrial	Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share.	16 Dec 2024	969	34,792 (0%)	0%	730.8	708,155	Common Stock
J Murphy Andrew	EVP Research	Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share.	16 Dec 2024	1,054	49,074 (0%)	0%	730.8	770,274	Common Stock
R. Fenimore Christopher	SVP Finance & CFO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share.	16 Dec 2024	491	16,265 (0%)	0%	730.8	358,828	Common Stock
Jason Pitofsky	VP Controller	Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share.	16 Dec 2024	298	4,664 (0%)	0%	730.8	217,781	Common Stock
Neil Stahl	EVP Research and Development	Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share.	16 Dec 2024	304	48,829 (0%)	0%	730.8	222,166	Common Stock
Neil Stahl	EVP Research and Development	Payment of exercise price or tax liability using portion of securities received from the company at price $ 787.00 per share.	09 Dec 2024	466	49,133 (0%)	0%	787	366,742	Common Stock
Joseph J. Larosa	EVP General Counsel and Secret	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	2,332	31,269 (0%)	0%		0	Common Stock
Joseph J. Larosa	EVP General Counsel and Secret	Payment of exercise price or tax liability using portion of securities received from the company at price $ 787.00 per share.	06 Dec 2024	492	30,777 (0%)	0%	787	387,204	Common Stock
Joseph J. Larosa	EVP General Counsel and Secret	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	8,981	8,981	-		-	Non-Qualified Stock Option (right to buy)
Daniel P. Van Plew	EVP & General Mgr, Industrial	Payment of exercise price or tax liability using portion of securities received from the company at price $ 787.00 per share.	06 Dec 2024	492	35,761 (0%)	0%	787	387,204	Common Stock
Daniel P. Van Plew	EVP & General Mgr, Industrial	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	3,499	36,253 (0%)	0%		0	Common Stock
Daniel P. Van Plew	EVP & General Mgr, Industrial	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	13,472	13,472	-		-	Non-Qualified Stock Option (right to buy)
Marion McCourt	EVP Commercial	Payment of exercise price or tax liability using portion of securities received from the company at price $ 787.00 per share.	06 Dec 2024	274	14,989 (0%)	0%	787	215,638	Common Stock
Marion McCourt	EVP Commercial	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	2,332	15,263 (0%)	0%		0	Common Stock
Marion McCourt	EVP Commercial	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	8,981	8,981	-		-	Non-Qualified Stock Option (right to buy)
Christopher R. Fenimore	SVP Finance & CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	9,979	9,979	-		-	Non-Qualified Stock Option (right to buy)
Christopher R. Fenimore	SVP Finance & CFO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 787.00 per share.	06 Dec 2024	1,140	16,756 (0%)	0%	787	897,180	Common Stock
Christopher R. Fenimore	SVP Finance & CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	2,591	17,896 (0%)	0%		0	Common Stock
Andrew J Murphy	EVP Research	Payment of exercise price or tax liability using portion of securities received from the company at price $ 787.00 per share.	06 Dec 2024	492	50,128 (0%)	0%	787	387,204	Common Stock
Andrew J Murphy	EVP Research	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	13,472	13,472	-		-	Non-Qualified Stock Option (right to buy)
Andrew J Murphy	EVP Research	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	3,499	50,620 (0%)	0%		0	Common Stock
Jason Pitofsky	VP Controller	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Dec 2024	3,236	3,236	-		-	Non-Qualified Stock Option (right to buy)

Showing 1 to 50 of 500 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

43.99% Fall from 52W High

Insider Trading disclosures for Regeneron Pharmaceuticals, Inc.

The latest disclosure was made by Arthur Frederick Ryan in Regeneron Pharmaceuticals, Inc. where a trade of 1,958 Non-Qualified Stock Option (right to buy) done was reported to US exchanges on Jan. 2, 2025.

Screeners based on Insider Trading and SAST parameters